Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine
for Migraine Prophylaxis
Drug: Atogepant
35 locations incl. Huntsville
Sponsor: AbbVie
Sex: All·Age: 6 - 17
Code: NCT05707949·Phase 3·Enrolling By Invitation